IK-175

Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Transcription factors, Clinical medicine, Aryl hydrocarbon receptor, Receptors, Medicine, Cancer immunotherapy, Immunotherapy, Bristol Myers Squibb, IK-175, Ikena Oncology

Ikena Oncology, Inc. (Ikena), a clinical-stage, biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced that a poster presentation will take place at the Society for Immunotherapy of Cancers (SITC) 2020 Annual Meeting, taking place virtually November 9-14, 2020.

Key Points: 
  • Ikena Oncology, Inc. (Ikena), a clinical-stage, biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced that a poster presentation will take place at the Society for Immunotherapy of Cancers (SITC) 2020 Annual Meeting, taking place virtually November 9-14, 2020.
  • New preclinical data will be presented for IK-175, the Companys selective oral aryl hydrocarbon receptor (AHR) antagonist currently in Phase 1 studies.
  • Activated AHR prevents immune recognition in a range of cancers by modulating both innate and adaptive immunity.
  • Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the AHR antagonist and Kynase programs.

Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade

Retrieved on: 
Wednesday, August 12, 2020
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Immune system, Transcription factors, Clusters of differentiation, T cells, Aryl hydrocarbon receptor, Receptors, Programmed cell death protein 1, Immunotherapy, Kynurenine, Regulatory T cell, IK-175, Ikena Oncology

The manuscript, titled, Blockade of the AHR restricts a Treg-Macrophage suppressive axis induced by L-Kynurenine, (Campesato, et al) describes the preclinical activity of aryl hydrocarbon receptor (AHR) blockade, alone and in combination with anti-PD-1 immunotherapy.

Key Points: 
  • The manuscript, titled, Blockade of the AHR restricts a Treg-Macrophage suppressive axis induced by L-Kynurenine, (Campesato, et al) describes the preclinical activity of aryl hydrocarbon receptor (AHR) blockade, alone and in combination with anti-PD-1 immunotherapy.
  • It further supports the potential of IK-175, Ikenas internally developed, orally administered, selective AHR antagonist currently in Phase 1 clinical development.
  • These data also point towards the potential for evaluating IK-175 in combination with an anti-PD-1 inhibitor.
  • In this preclinical study, which includes use of an Ikena AHR antagonist similar to IK-175, researchers demonstrated that AHR blockade reverses IDO/TDO-mediated immunosuppression.

Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, January 28, 2020
Biotechnology, Other Health, Health, Clinical trials, Oncology, Cancer research, Response Evaluation Criteria in Solid Tumors, Medicine, Health, Prodrugs, Medical physics, Radiobiology, IK-175, Ikena Oncology

This Phase 1 study is expected to enroll approximately 50 patients in the US across both the dose escalation and dose expansion portions of the study.

Key Points: 
  • This Phase 1 study is expected to enroll approximately 50 patients in the US across both the dose escalation and dose expansion portions of the study.
  • The primary objectives of the study include determination of the maximum tolerated dose, characterizing dose-limiting toxicities, and identification of the recommended Phase 2 dose of single-agent IK-175.
  • Secondary objectives include evaluating disease response, including overall response rate, progression-free survival, duration of treatment, disease control rate and duration of response, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Ikena Oncology recently commenced a first-in-human, Phase 1 clinical study ( NCT04200963 ) in which the safety and antitumor activity of IK-175 is being evaluated as a single agent in advanced solid tumors.